VKTX - バイキング・セラピュ―ティクス （Viking Therapeutics Inc.） バイキング・セラピュ―ティクスVKTXのチャート
VKTXの企業情報
| symbol | VKTx |
|---|---|
| 会社名 | Viking Therapeutics Inc （バイキング・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 バイキング･セラピューティクス(Viking Therapeutics Inc.)は臨床段階バイオ医薬品会社である｡同社は代謝及び内分泌障害治療法の開発に焦点を当てる｡そのリード臨床プログラムVK5211は､第II相臨床試験下での経口投与可能な薬剤候補である｡第二の臨床プログラムは､高コレステロール血症及び非アルコール性脂肪性肝炎（NASH）等副腎白質ジストロフィー（ALD）及び脂質障害のための甲状腺受容体ベータ（TRB）の分子アゴニストの開発に焦点を当てる｡同社はまた､ALDの治療･潜在性予防のためのVK2809及びVK0214の開発に従事する｡VK0612は､2型糖尿病ための経口投与可能な第IIb相対応薬剤候補である｡同社の前臨床プログラムは､貧血治療用エリスロポエチン受容体（EPOR）アゴニストの同定､及び肥満症及び脂質異常症治療用ジアシルグリセロールアシルトランスフェラーゼ-1（DGAT-1）の組織･選択的阻害剤の開発に焦点を当てる｡ バイキング・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。代謝及び内分泌疾患のための新規治療法の開発に焦点を当てる。主な臨床プログラムには、股関節骨折手術後のための非ステロイド系アンドロゲン受容体モジュレ―タ―の経口薬「VK5211」がある。また、副腎白質ジストロフィ―のための、小分子で経口投与可能な甲状腺受容体ベ―タを開発中。 Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated. |
| 本社所在地 | 12340 El Camino Real Suite 250 San Diego CA 92130 USA |
| 代表者氏名 | Lawson Macartney ローソン・マッカートニー |
| 代表者役職名 | independent Chairman of the Board |
| 電話番号 | +1 858-704-4660 |
| 設立年月日 | 41153 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2015年 |
| 従業員数 | － |
| url | www.vikingtherapeutics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/vktx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -20.84878 |
| 終値（lastsale） | 14.74 |
| 時価総額（marketcap） | 894095883.56 |
| 時価総額 | 時価総額（百万ドル） 973.01920 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 830.85320 |
| 当期純利益 | 当期純利益（百万ドル） -20.40713 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Viking Therapeutics Inc revenues was not reported. Net loss decreased 2% to $10.2M. Lower net loss reflects Interest Expense/Income - Net increase from $3K (expense) to $573K (income) Change in fair value of debt conversion increase of 65% to $1.4M (income) Amortization of financing costs decrease of 88% to $60K (expense). |
VKTXのテクニカル分析
VKTXのニュース
Why Viking Therapeutics Stock Wobbled Today 2023/05/09 19:40:21 The Motley Fool
The biotech''s shares dipped along with the broader markets in early-morning trading today.
Brinker Capital Investments LLC Makes New $95,000 Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX) 2023/05/09 09:08:47 The AM Reporter
Brinker Capital Investments LLC acquired a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,055 shares of the biotechnology company’s stock, valued at approximately $95,000. Other hedge funds also recently added to or […]
Viking Therapeutics off 5% following CEO stock sale 2023/05/02 19:08:37 Seeking Alpha
Viking Therapeutics is down ~5% Tuesday following the disclosure that CEO Brian Lian sold shares. Read more here.
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today 2023/05/01 20:28:20 The Motley Fool
These three biotech stocks were on the volatile side today.
Why Viking Therapeutics Stock Briefly Popped Today | The Motley Fool 2023/04/27 18:56:13 The Motley Fool
The biotech''s shares rose briefly this morning following a sizable price target revision by an investing firm.
Why Viking Therapeutics Stock Briefly Popped Today | The Motley Fool 2023/04/27 18:56:13 The Motley Fool
The biotech''s shares rose briefly this morning following a sizable price target revision by an investing firm.
H.C. Wainwright maintains Viking Therapeutics Inc at Buy with a price target of $33.00 2023/04/27 14:16:37 Investing.com
https://www.investing.com/news/pro/viking-therapeutics-inc-receives-investment-bank-analyst-rating-update-3066478
Viking Therapeutics, Inc. (VKTX) Q1 2023 - Earnings Call Transcript 2023/04/27 00:55:18 Seeking Alpha
Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) Q1 2023 Earnings Conference Call April 26, 2023 4:30 PM ETCompany ParticipantsStephanie Diaz - Manager of Investor RelationsBrian Lian -…
Viking Therapeutics GAAP EPS of -$0.25 misses by $0.01 2023/04/26 20:08:32 Seeking Alpha
Viking Therapeutics press release (VKTX): Q1 GAAP EPS of -$0.25 misses by $0.01.At March 31, 2023, Viking held cash, cash equivalents and short-term investments of $135.7…
Viking Therapeutics (NASDAQ:VKTX) Price Target Increased to $35.00 by Analysts at Oppenheimer 2023/04/26 08:10:45 The AM Reporter
Viking Therapeutics (NASDAQ:VKTX – Get Rating) had its target price lifted by Oppenheimer from $30.00 to $35.00 in a report released on Tuesday morning, The Fly reports. A number of other brokerages have also issued reports on VKTX. StockNews.com assumed coverage on shares of Viking Therapeutics in a report on Thursday, March 16th. They issued […]
Why Shares of Viking Therapeutics Skyrocketed This Week 2023/03/30 18:06:33 The Motley Fool
The clinical-stage stock nearly doubled in price.
Thursday’s Top Analyst Upgrades and Downgrades: Abbott Labs, Carnival, Delta Air Lines, First Republic Bank, Lululemon, Macy’s, Marathon Petroleum, Micron Technology and More 2023/03/30 12:55:54 24/7 Wall street
Thursday''s top analyst upgrades and downgrades included Abbott Laboratories, Carnival, Deere, Delta Air Lines, DexCom, Enovix, First Republic Bank, GitLab, Hartford Financial Services, Interpublic Group, Invesco, Lululemon Athletica, Macy’s, Marathon Petroleum, Medtronic, Micron Technology, Nextracker, Viking Therapeutics and Vipshop.
Viking Therapeutics Prices 17.24M Share Offering at $14.50/sh 2023/03/30 09:55:05 Investing.com
https://www.investing.com/news/assorted/viking-therapeutics-prices-1724m-share-offering-at-1450sh-432SI-3044833
Viking Therapeutics sheds on pricing $250M stock offering 2023/03/30 09:06:37 Seeking Alpha
Viking Therapeutics (VKTX) shares are down 4.27% premarket after the firm has priced its underwritten public offering of 17.24M shares of its common stock at a price to the public…
Viking Therapeutics (NASDAQ:VKTX) Given New $35.00 Price Target at Raymond James 2023/03/30 09:00:41 The AM Reporter
Viking Therapeutics (NASDAQ:VKTX – Get Rating) had its target price hoisted by Raymond James from $12.00 to $35.00 in a research note published on Wednesday morning, The Fly reports. They currently have an outperform rating on the biotechnology company’s stock. Several other analysts have also issued reports on the stock. Oppenheimer upped their target price […]